Last updated: 4 July 2020 at 1:04pm EST

John A Tattory Net Worth




The estimated Net Worth of John A Tattory is at least $28.3 Tausend dollars as of 22 May 2020. John Tattory owns over 449 units of Windtree Therapeutics stock worth over $28,304 and over the last 6 years John sold WINT stock worth over $0.

John Tattory WINT stock SEC Form 4 insiders trading

John has made over 1 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently John bought 449 units of WINT stock worth $3,255 on 22 May 2020.

The largest trade John's ever made was buying 449 units of Windtree Therapeutics stock on 22 May 2020 worth over $3,255. On average, John trades about 150 units every 0 days since 2019. As of 22 May 2020 John still owns at least 9,280 units of Windtree Therapeutics stock.

You can see the complete history of John Tattory stock trades at the bottom of the page.



What's John Tattory's mailing address?

John's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.

Insiders trading at Windtree Therapeutics

Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... und Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.



What does Windtree Therapeutics do?

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.



What does Windtree Therapeutics's logo look like?

Windtree Therapeutics, Inc. logo

Complete history of John Tattory stock trades at Windtree Therapeutics

Datum
#
Unternehmen
Insider
Trans.
Transaktion
Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
22 May 2020 John A Tattory
SVP und CFO
Kauf 449 $7.25 $3,255
22 May 2020
9,280


Windtree Therapeutics executives and stock owners

Windtree Therapeutics executives and other stock owners filed with the SEC include: